If any of these "doctors" had real facts, their points would have been clearly made and supported and the price of Zonagen would have stayed in the single digits. The negative posts have appeared since April, both here and on the Motley Fool boards. Anyone who takes the time to verify what these posters claim soon find they are dealing with deliberate disinformation. Facts are taken out of context. New data is ignored, such as the Phase 2 and 3 trials for Vasomax which showed excellent safety. Some posts contained outright lies, such as Tuna's claim that an article he cited shows phentolamine to be a non-issue. In actuality, all the author said was that as of the date of the article(early 1996), data was insufficient for evaluation. As we all know, much data has been presented since then.
Those who shorted Zonagen back in April, when the stock was in the mid teens, have had their heads handed to them (gg, hd). No doubt, some diehards will attempt to continue this behavior. Hopefully, they will short the stock. It will be fun to watch Zona climb after the announcement of a deal, fueled by those who want to buy and those shorts who must cover.
The Pfizer announcement is not wholly unexpected. They pre-announced this about two months ago. Remember, FDA review can take from six months to a year and a half or more. The fact that Pfizer accelerated their timetable indicates to me that they see the vast potential in this market. Zonagen could still beat them to market with the right partner. If not, Vasomax still has advantages in price, time of onset and less side effects. There is a huge and growing market out there and with 12 - 13 million shares, fully diluted, Zona shareholders stand to profit very nicely as a first line therapy for ED.
IMHO, any pullback tomorrow creates a buying opportunity....and a bear trap! |
